Format

Send to

Choose Destination
Blood Transfus. 2016 Mar;14(2):175-84. doi: 10.2450/2015.0096-15. Epub 2015 Dec 16.

The evolution of anticoagulant therapy.

Author information

1
Department of Haematology and Transfusion Medicine, Carlo Poma Hospital, Mantua, Italy.
2
Italian National Blood Centre, National Institute of Health, Rome, Italy.
3
Section of Clinical Biochemistry, University of Verona, Verona, Italy.

Abstract

Arterial and venous thromboembolism are leading causes of morbidity and mortality around the world. For almost 70 years, heparins (unfractionated heparin and low molecular weight heparins) and vitamin K antagonists have been the leading therapeutic medical options for the treatment and prevention of thromboembolic disorders. Nevertheless, the many limitations of these traditional anticoagulants have fuelled the search for novel agents over the past 15 years, and a new class of oral anticoagulants that specifically target activated factor X and thrombin has been developed and is now commercially available. In this narrative review, the evolution of anticoagulant therapy is summarised, with a focus on newer oral anticoagulants.

PMID:
26710352
PMCID:
PMC4781787
DOI:
10.2450/2015.0096-15
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Data Conversion Labs Icon for PubMed Central
Loading ...
Support Center